$137 Million for a Cancer Drug That Doesn't Exist Yet

A Lead Program, But No Clinic Yet

The company's lead program is a bispecific ADC aimed at solid tumors. The specific receptor targets haven't been disclosed publicly, which is fairly standard for a preclinical company trying to keep competitors guessing. Sidewinder says it's running IND-enabling studies (the preclinical work required before filing to start human trials) and expects to file its IND by the end of 2026, with clinical trials beginning in 2027.

Beyond the lead program, the pipeline focuses on cancers with limited treatment options: squamous cell carcinomas of the lung and head and neck, along with gastrointestinal cancers including colorectal cancer. None of these additional programs have disclosed specific timelines.

To strengthen its manufacturing backbone, Sidewinder signed a multi-target licensing deal in January 2026 with Lonza's Synaffix unit. That gives it access to Synaffix's proprietary conjugation technology (GlycoConnect, HydraSpace, and toxSYN platforms), which helps attach payloads to antibodies more precisely and consistently. Think of it as upgrading from hand-soldering bombs onto rockets to having a robotic assembly line do it.

Why Investors Can't Stop Writing Checks for ADCs

Sidewinder's fundraise isn't happening in a vacuum. The ADC space has been on an absolute tear, and 2025-2026 has been a dealmaking frenzy.

The biggest headline: Gilead Sciences acquired Tubulis for $3.15 billion upfront (plus up to $1.85 billion in milestones) in 2026, snapping up two clinical-stage ADCs and a platform for building better linkers and payloads. That was Gilead's third acquisition of the year.

The licensing deals have been just as aggressive. Astellas paid $130 million upfront for global rights to a CLDN18.2-targeted ADC from Evopoint Biosciences in 2025, with milestones totaling up to $1.34 billion. Innovent licensed a DLL3 ADC to Roche with milestones up to $1 billion. DualityBio and Avenzo struck a deal worth up to $1.15 billion for a bispecific ADC.

The pattern is unmistakable: big pharma is hungry for ADC assets, and they're willing to pay billions to get them. That dynamic turns every well-funded ADC startup into a potential acquisition target, which is exactly the kind of math that makes venture investors salivate.

Other ADC startups have been cashing in on this momentum. NEOK Bio emerged from stealth in November 2025 with a $75 million Series A to advance bispecific ADCs. Tubulis had raised $361 million in a Series C back in October 2025 before Gilead came knocking. OrbiMed itself participated in Adcendo's $135 million Series B and Avenzo's $60 million Series B in recent years.

The Team Behind the Snake

Sidewinder was co-founded by Eric Murphy, Ph.D., who serves as CEO, and Ryan Corcoran, M.D., Ph.D. Murphy brings over 20 years in oncology drug development, with stints at Crown Bioscience and Novartis-GNF, plus co-founding roles at Kinnate Biopharma and Alterome Therapeutics. Corcoran runs labs at Massachusetts General Hospital and Harvard, focusing on tumor mutations and liquid biopsies.

With the Series B, four new board members joined: Daniel Estes from Frazier, Michal Silverberg from Novartis Venture Fund, Josh Richardson from Goldman Sachs Alternatives, and John Hamer from DCVC Bio. That's a lot of heavyweight names for a company that won't treat its first patient until next year.

The $137 Million Question

Is Sidewinder worth the hype? There's genuine science here. Bispecific ADCs represent a real advancement in targeting precision, and the company's "two-key" approach could meaningfully widen the therapeutic window (more killing of cancer cells, less damage to everything else). The founding team has serious credentials, and the manufacturing partnership with Synaffix adds credibility.

But let's be honest about the risks. Every dollar of that $137 million is riding on preclinical data. No human has ever received a Sidewinder ADC infusion. The jump from "works in the lab" to "works in patients" is where most cancer drugs go to die; roughly 95% of oncology drugs that enter clinical trials never make it to approval.

The bullish case? Even if the lead program stumbles, the platform itself could be valuable. With big pharma vacuuming up ADC assets at multi-billion-dollar price tags, Sidewinder doesn't necessarily need an approved drug to generate a massive return for its investors. It just needs compelling enough clinical data to attract a buyer.

For now, that's a $137 million bet on a snake that hasn't bitten yet. The clinic will tell us whether it has venom or just fangs.

Biogen's Bet on a Twisted Piece of Chemistry

Biogen just partnered with Alloy Therapeutics to access a platform that literally reshapes antisense drugs at the molecular level. It's a quiet deal that could unlock targets the company's existing toolkit can't touch.